Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in the development of its gene-agnostic therapy, OCU400, as the European Commission has delivered a positive opinion designating it ...
Live Ventures Incorporated (Nasdaq: LIVE) ("Live Ventures" or the "Company"), a diversified holding company, today announced financial results for its fiscal ...
Proterra Investment Partners LP ("Proterra"), a Minneapolis-based alternative asset manager focused on private equity and private credit investments across the food value chain, announced today that ...